Dual Path Platform (DPP) Vet Tuberculosis (TB) Assay Kits
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
This requirement is for Dual Path Platform (DPP) Vet Tuberculosis (TB) Assay kits. These are single use immune-chromatographic tests for detection of antibodies to Mycobacterium Bovis in cervid samples and is the official test for the Federal Bovine Tuberculosis Eradication program. The test is used for the diagnosis of tuberculosis in conjunction with other diagnostic methods. quantitative analysis.
RFO FAR 12.201-1 Simplified procedures will be used for awarding this contract. The anticipated award date is January 22, 2026.
The intended source for this acquisition is Chembio Diagnostic Systems, Inc.
The proposed contractor, Chembio Diagnostic Systems, Inc. is the only company that currently has a licensed test kit to detect antibodies in cervids for bovine tuberculosis. Chembio’s Cervid DPP is the only test that has approval to be used as part of the TB eradication program.
All responsible sources may submit a response which will be considered by the agency. Please email responses to Kathy Melby at Kathleen.melby@usda.gov no later than the response date of this notice. Telephonic inquiries will not be honored.